28 Jan 2020
In the fourth elproINTERVIEW, the ELPRO management team talks about how ELPRO 2023 has set the course for the realignment of the company and its solution portfolio.
2023 posed major challenges for the pharmaceutical industry in particular and resulted in extremely subdued growth. And even though the market is already expected to pick up again in 2024, ELPRO has used the past year to set an important course for the realignment of the company and its solution portfolio.
In the fourth and final elproINTERVIEW this year, the members of the management team, Josef Schmid, Philipp Osl, Christoph Bamert and Björn Niggemann, have their say. They talk about what made 2023 a special year for them and give an insight into what ELPRO's customers and partners can expect from the new year 2024.